Activin and estrogen crosstalk regulates transcription in human breast cancer cells.

Activin is a member of the transforming growth factor beta superfamily that regulates mammary cell function during development, lactation, and in cancer. Activin slows the growth of breast cancer cells by inducing G(0)/G(1) cell cycle arrest. Estrogen is a steroid hormone that stimulates the proliferation of mammary epithelial cells in development and oncogenesis. The crosstalk between estrogen and activin that regulates activin ligand expression, activin and estrogen signal transduction, and cell cycle arrest was investigated in this study. Estrogen antagonized activin-dependent production of plasminogen activator inhibitor 1 (PAI-1) mRNA, while activin repressed estrogen-dependent transcription of trefoil factor 1. The repression of estrogen signaling by activin was recapitulated using a simple estrogen response element-luciferase construct and was enhanced in the presence of overexpressed estrogen receptor alpha (ERalpha). In contrast, estrogen-mediated repression of activin signaling could not be recapitulated on a simple CAGA Smad-binding element but did inhibit the short PAI-1 promoter, p3TP-luciferase, especially when ERalpha was overexpressed. Repression of both estrogen- and activin-regulated transcription was found to be ligand induced and Smad3 dependent. In addition to transcriptional repression, estrogen also reduced the amount of activin B mRNA and protein produced by MCF7 breast cancer cells. These studies demonstrate the importance of activin and estrogen crosstalk during mammary cell growth and cancer initiation.

[1]  N. Gebbia,et al.  Activin A circulating levels in patients with bone metastasis from breast or prostate cancer , 2006, Clinical & Experimental Metastasis.

[2]  R. Gust,et al.  17-β-estradiol inhibits transforming-growth-factor-β-induced MCF-7 cell migration by Smad3-repression , 2006 .

[3]  E. Ariazi,et al.  Estrogen receptors as therapeutic targets in breast cancer. , 2006, Current topics in medicinal chemistry.

[4]  R. Gust,et al.  17-Beta-estradiol inhibits transforming-growth-factor-beta-induced MCF-7 cell migration by Smad3-repression. , 2006, European journal of pharmacology.

[5]  E. J. Lee,et al.  Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. , 2005, Cancer research.

[6]  R. Keri,et al.  Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice , 2005, Oncogene.

[7]  Yi Sun,et al.  Smad4 Inhibits Tumor Growth by Inducing Apoptosis in Estrogen Receptor-α-positive Breast Cancer Cells* , 2005, Journal of Biological Chemistry.

[8]  Horst Buerger,et al.  First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor‐positive breast cancer , 2005, The Journal of pathology.

[9]  B. Long,et al.  The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. , 2005, Cancer research.

[10]  R. Nicholson,et al.  Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  U. Jeschke,et al.  Inhibin/activin subunits (inhibin-α, -βA and -βB) are differentially expressed in human breast cancer and their metastasis , 2005 .

[12]  U. Jeschke,et al.  Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis. , 2005, Oncology reports.

[13]  S. Ying,et al.  Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line , 2005, Breast Cancer Research and Treatment.

[14]  F. Vizoso,et al.  Tissue-Type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance , 2005, Breast Cancer Research and Treatment.

[15]  F. Petraglia,et al.  Activin, inhibin and the human breast , 2004, Molecular and Cellular Endocrinology.

[16]  K. Pfizenmaier,et al.  Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. , 2004, Molecular endocrinology.

[17]  G. Lanuza,et al.  Activin and follistatin in rat mammary gland , 2004, Molecular and Cellular Endocrinology.

[18]  J. Frasor,et al.  Therapeutic targeting in the estrogen receptor hormonal pathway. , 2004, Seminars in oncology.

[19]  Bert W O'Malley,et al.  Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.

[20]  D. Tong,et al.  Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor‐1 in human breast cancer cell lines , 1999, Breast Cancer Research and Treatment.

[21]  Minetta C. Liu,et al.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.

[22]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[23]  A. Rademaker,et al.  Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. , 2003, Cancer research.

[24]  B. Katzenellenbogen,et al.  Modulation of estrogen receptor activity by selective coregulators , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  W. Grizzle,et al.  Smad4 as a Transcription Corepressor for Estrogen Receptor α* , 2003, The Journal of Biological Chemistry.

[26]  M. Low,et al.  Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Knabbe,et al.  Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. , 2003, Anticancer research.

[28]  E. Anderson.  Progesterone receptors – animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis , 2002, Breast Cancer Research.

[29]  D. Bernard,et al.  Photoperiod-dependent regulation of inhibin in Siberian hamsters: I. Ovarian inhibin production and secretion. , 2002, The Journal of endocrinology.

[30]  Tetsuya Yamamoto,et al.  Cross-talk between bone morphogenic proteins and estrogen receptor signaling. , 2002, Endocrinology.

[31]  F. Petraglia,et al.  Serum and tissue expression of activin a in postmenopausal women with breast cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[32]  S. Pangas,et al.  Production and purification of recombinant human inhibin and activin. , 2002, The Journal of endocrinology.

[33]  Tetsuya Yamamoto,et al.  Cross-talk between Transforming Growth Factor-β and Estrogen Receptor Signaling through Smad3* , 2001, The Journal of Biological Chemistry.

[34]  Serge Lemay,et al.  The p38 MAPK Pathway Is Required for Cell Growth Inhibition of Human Breast Cancer Cells in Response to Activin* , 2001, The Journal of Biological Chemistry.

[35]  I. Mowszowicz,et al.  Estrogen and antiestrogen actions on transforming growth factorβ (Tgfβ) in normal human breast epithelial (HBE) cells , 2001, Molecular and Cellular Endocrinology.

[36]  D. Peehl,et al.  SMAD3 represses androgen receptor-mediated transcription. , 2001, Cancer research.

[37]  I. Mowszowicz,et al.  Estrogen and antiestrogen actions on transforming growth factorbeta (TGFbeta) in normal human breast epithelial (HBE) cells. , 2001, Molecular and cellular endocrinology.

[38]  J. Robertson,et al.  Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.

[39]  C. Zuiani,et al.  Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. , 1999, European journal of endocrinology.

[40]  K. Miyazono,et al.  Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. , 1999, Science.

[41]  R. Clarke,et al.  Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. , 1999, Journal of the National Cancer Institute.

[42]  G. Pittman.  Tissue-type plasminogen activator. , 1998, Archives of neurology.

[43]  V. Jordan,et al.  Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. , 1998, British Journal of Cancer.

[44]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[45]  V. Jordan,et al.  Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. , 1998, Cancer letters.

[46]  L. Hennighausen,et al.  Inhibins and activins regulate mammary epithelial cell differentiation through mesenchymal-epithelial interactions. , 1997, Development.

[47]  B. Katzenellenbogen,et al.  Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[48]  R. Coombes,et al.  Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. , 1996, Cancer research.

[49]  Adriana,et al.  Resistance to Transforming Growth Factor 1 and Activin Due to Reduced Receptor Expression in Human Breast Tumor Cell Lines ’ , 2005 .

[50]  R. Jaenisch,et al.  Functional analysis of activins during mammalian development , 1995, Nature.

[51]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.